Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma

Hybridoma

Volumn 19, Issue 1, 2000, Pages 33-41

  Kriangkum, Jitra ^a   Xu, Biwen ^a   Gervais, Christian ^b   Paquette, Denis ^b   Jacobs, Frederik A ^b   Martin, Luis ^b   Suresh, Mavanur R ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNOASSAY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CA-125 ANTIGEN; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GROWTH INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

ANIMALIA; MAMMALIA;

EID: 0034080840     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245700315770     Document Type: Article

References (37)

1. Renner C, and Pfreundschuh M: Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 1995;145:179-209.
2. Cao Y, and Suresh MR: Bispecific antibodies as novel bioconjugates. Bioconjugate Chem 1998;9:635-644.
3. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Funke I, and Riethmuller G: Frequent down-regulation of major histocompatibility Class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991;51:4712-4715.
4. Demanet C, Brissinck J, Leo O, Moser M, and Thielemans K: Role of T-cell subsets in the bispecific antibody (anti-idiotypexanti-CD3) treatment of the BCL1 lymphoma. Cancer Res 1994;54:2973-2978.
5. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, and Wunderlich JR: Targeting human T lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells in nu/nu mice. Cancer Res. 1990;50:4227-4232.
6. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Hartmann F, Diehl V, Van Lier R, and Pfreundschuh M: Cure of xenografted human tumors by bispecific antibodies and human T cells. Science 1994;264:833-835.
7. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, et al.: Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpress HER-2/neu. J Hematother 1995;4:471-475.
8. Weiner LM, Clark JI, Ring DB, and Alpaugh RK: Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995;4:453-456.
9. Kroesen BJ, Ter Haar A, Spakman H, Willemse P, Steijfer DT, De Vries EGE, Mulder NH, Berendsen HH, Limburg PC, Teh TH, and De Leij L: Local anti-tumour treatment in carcinoma patients with bispecific monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 1993;37:400-407.
10. Raso V, and Griffin T: Hybrid antibody with dual specificity for the delivery of ricin to immunoglobulin bearing target cells. Cancer Res 1981;41:2073-2078.
11. Pohl C, Denfeld R, Renner C, Jung W, Bohlen H, Sahlin U, Hombach A, van Lier R, Schwonzen F, Diehl V, and Pfreundschuh M: CD30 antigen specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD30 and CD28. Int J Cancer 1993;54:820-827.
12. Winter G, and Milstein C: Man-made antibodies. Nature 1991;349:293-299.
13. Pluckthun A, and Pack P: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105.
14. Holliger P, and Winter G: Diabodies: Small bispecific antibody fragments. Cancer Immunol Immunother 1997;45:128-130.
15. Mack M, Riethmuller G, and Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. PNAS 1995;92:7021-7025.
16. Jost CR, Titus JA, Kurucz I, and Segal DM: A single chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol Immunol 1996;33:211-219.
17. Kurucz I, Titus JA, Jost CR, Jacobus CM, and Segal DM: Retargeting CTL by an efficiently refolded bispecific single chain Fv dimer produced in bacteria. J Immunol 1995;154:4576-4582.
18. Mallender WD, and Voss EWJ: Construction, expression and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994;269:199-206.
19. Leo O, Foo M, Sachs DH, Samelson LE, and Bluestone JA: Identification of a monoclonal antibody specific for a murine T3 polypeptide. PNAS 1987;84:1374-1378.
20. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnesrstag B, Sykes T, Boniface G, and Hor G: Clinical course of ovarian cancer patients under repeated stimulation of HAMA using mAB OC125 and B43.13. Hybridoma 1993;12:583.
21. Krantz MJ, Maclean G, Longenecker BM, and Suresh MR: A radioimmunoassay for CA125 employing two new monoclonal antibodies. J Cell Biochem 1988; (suppl. 12)E:139.
22. Kreutz FT, and Suresh MR: Bispecific monoclonal anti-CA125 × anti-peroxidase antibodies in the measurement of the ovarian carcinoma antigen. J Tumor Marker Oncol 1995;10:45-53.
23. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, and Hor G: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73:1121.
24. Kreutz FT, Xu D, and Suresh MR: A new method to generate quadromas by electrofusion and FACS sorting. Hybridoma 1997;17:267-273.
25. Nilson BH, Logdberg L, Kastern W, Bjorck L, and Akerstrom B: Purification of antibodies using protein L-binding framework structures in the light chain variable domain. J Immunol Methods 1993;164:33-40.
26. Van Dijk J, Zegveld ST, Fleuren GJ, and Warnaar SO: Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991;48:738-743.
27. Knuth A, Bernhard H, Jager E, Wolfel T, Karbach J, Jaggle C, Strittmatter W, and Meyer Zum Buschenfelde KH: Induction of tumor cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3. Eur J Cancer 1994;30a:1103-1107.
28. Ohta S, Tsukamoto H, Watanabe K, Makino K, Kuge S, Hanai N, Habu S, and Nishimura T: Tumor associated glycoantigen, sialyl Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol Lett 1995;44:35-40.
29. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, et al.: Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: A multicenter study. Int J Cancer 1992;7(suppl.):78-81.
30. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Alexander MM, Eggermont AM, Goey SH, Gratama JW, Lamers CH, et al.: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87:1463-1469.
31. Chapoval AI, Nelson H, and Thibault C: Anti-CD3xanti-tumor F(ab′)2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. J Immunol 1995;155:1296-1303.
32. De Gast GC, Haagen IA, Houten AA, et al.: CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patient with non-Hodgkin lymphoma. Cancer Immunol Immunother 1995;40:390.
33. Suresh MR, Cuello C, and Milstein C: Bispecific monoclonal antibodies from hybrid hybridomas. Meth Enzymol 1986;121: 210-228.
34. Luo D, Geng M, Noujaim AA, and Madiyalakan R: An engineered bivalent single chain antibody fragment that increases antigen binding activity. J Biochem 1997;121:831-834.
35. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickrammanayake D, Diehl V, and Tesch H: Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T-cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993;82:1803-1812.
36. Jung G, Freimann Z, Von Marschall R, Reisfeld A, and Wilmanns W: Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 1991;21:2431-2435.
37. Beun GDM, Gorter A, Nooyen Y, Velde CJHvd, and Fleuren GJ: T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. J Immunol 1993;150:2305-2315.